Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility

Journal of Neurochemistry

Volumn 124, Issue 1, 2013, Pages 69-78

  Frau, Lucia ^a   Simola, Nicola ^a   Plumitallo, Antonio ^a   Morelli, Micaela ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

CD11b; ecstasy; GFAP; hyperthermia; neurodegeneration; neuroinflammation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORPUS STRIATUM; ENANTIOMER; HYPERTHERMIA; IN VIVO STUDY; MACROGLIA; MALE; MICROGLIA; MOTOR ACTIVITY; MOTOR CORTEX; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RACEMIZATION; SUBSTANTIA NIGRA;

ANIMALS; ANTIGENS, CD11B; ASTROCYTES; BODY TEMPERATURE; BRAIN; DRUG INTERACTIONS; HALLUCINOGENS; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STEREOISOMERISM;

MUS;

EID: 84870917977     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12060     Document Type: Article

References (39)

1. Acquas E., Pisanu A., Spiga S., Plumitallo A., Zernig G., and, Di Chiara G., (2007) Differential effects of intravenous R, S-(+/-)-3,4- methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core. J. Neurochem. 102, 121-132. (Pubitemid 46906254)
2. von Ameln N., and, von Ameln-Mayerhofer A., (2010) Atypical development&of behavioural sensitization to 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy') in adolescent rats and its expression in adulthood: role of the MDMA chirality. Addict. Biol. 15, 35-44.
3. Borch R. F., Bernstein M. D., and, Dupont Durst H., (1971) Cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 93, 2897-2904.
4. Capela J. P., Macedo C., Branco P. S., et al,. (2007) Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146, 1743-1757. (Pubitemid 46795533)
5. Carta A. R., Kachroo A., Schintu N., Xu K., Schwarzschild M. A., Wardas J., and, Morelli M., (2009) Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 111, 1478-1489.
6. Colado M. I., Granados R., O'Shea E., Esteban B., and, Green A. R., (1998) Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. Br. J. Pharmacol. 124, 479-484. (Pubitemid 28254503)
7. Delle Donne K. T., and, Sonsalla P. K., (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271, 1320-1326. (Pubitemid 24382640)
8. Fantegrossi W. E., (2008) In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp. Clin. Psychopharmacol. 16, 1-12. (Pubitemid 351305490)
9. Fantegrossi W. E., Godlewski T., Karabenick R. L., Stephens J. M., Ullrich T., Rice K. C., and, Woods J. H., (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166, 202-211. (Pubitemid 36384765)
10. Fantegrossi W. E., Murai N., Mathúna B. O., Pizarro N., and, de la Torre R., (2009) Discriminative stimulus effects of 3,4- methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J. Pharmacol. Exp. Ther. 329, 1006-1015.
11. Frau L., Borsini F., Wardas J., Khairnar A. S., Schintu N., and, Morelli M., (2011) Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse 65, 181-188.
12. Gluck M. R., Moy L. Y., Jayatilleke E., Hogan K. A., Manzino L., and, Sonsalla P. K., (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152-160. (Pubitemid 32946652)
13. Granado N., Escobedo I., O'Shea E., Colado I., and, Moratalla R., (2008a) Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 62, 80-84. (Pubitemid 350156147)
14. Granado N., O'Shea E., Bove J., Vila M., Colado M. I., and, Moratalla R., (2008b) Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J. Neurochem. 107, 1102-1112.
15. Green A. R., Mechan A. O., Elliott J. M., O'Shea E., and, Colado M. I., (2003) The pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55, 463-508. (Pubitemid 37013213)
16. Halliday G. M., and, Stevens C. H., (2011) Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 26, 6-17.
17. Hass H. B., Susie A. G., and, Heider R. L., (1950) Nitro alkene derivatives. J. Org. Chem. 15, 8-14.
18. Hayat S., Williams R. J., and, Rattray M., (2006) Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4- methylenedioxymethamphetamine (MDMA) in vitro. J. Psychopharmacol. 20, 257-263.
19. Hiramatsu M., Nabeshima T., Kameyama T., Maeda Y., and, Cho A. K., (1989) The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol. Biochem. Behav. 33, 343-347. (Pubitemid 19245517)
20. Johnson E. A., Shvedova A. A., Kisin E., O'Callaghan J. P., Kommineni C., and, Miller D. B., (2002) d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res. 933, 150-163. (Pubitemid 34270619)
21. Khairnar A., Plumitallo A., Frau L., Schintu N., and, Morelli M., (2010) Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox. Res. 17, 435-439.
22. Lebsanft H. B., Kohles T., Kovar K. A., and, Schmidt W. J., (2005) 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy. Synapse 55, 148-155. (Pubitemid 40194716)
23. Lim H. K., Su Z., and, Foltz R. L., (1993) Stereoselective disposition: enantioselective quantitation of 3,4-(methylenedioxy) methamphetamine and three of its metabolites by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biol. Mass Spectrom. 22, 403-411. (Pubitemid 23187115)
24. Mechan A. O., O'Shea E., Elliott J. M., Colado M. I., and, Green A. R., (2001) A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology 155, 413-418. (Pubitemid 32523112)
25. Meyer M. R., and, Maurer H. H., (2009) Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem. Res. Toxicol. 22, 1205-1211.
26. Meyer A., Mayerhofer A., Kovar K. A., and, Schmidt W. J., (2002) Enantioselective metabolism of the designer drugs 3,4- methylenedioxymethamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') isomers in rat brain and blood. Neurosci. Lett. 330, 193-197. (Pubitemid 35257897)
27. Miller D. B., and, O'Callaghan J. P., (1995) The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol. Neurobiol. 11, 177-192.
28. Nichols D. E., Hoffman A. J., Oberlender R. A., Jacob P. III, and, Shulgin A. T., (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J. Med. Chem. 29, 2009-2015. (Pubitemid 16030310)
29. O'Callaghan J. P., and, Miller D. B., (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751. (Pubitemid 24271391)
30. O'Callaghan J. P., and, Sriram K., (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin. Drug Saf. 4, 433-442. (Pubitemid 40723718)
31. Paxinos G., and, Franklin K. B. J., (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
32. Rattray M., (1991) Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 26, 77-87.
33. Reveron M. E., Monks T. J., and, Duvauchelle C. L., (2005) Age-dependent (+)MDMA-mediated neurotoxicity in mice. Neurotoxicology 26, 1031-1040. (Pubitemid 41681300)
34. Schenk S., (2009) MDMA self-administration in laboratory animals: a summary of the literature and proposal for future research. Neuropsychobiology 60, 130-136.
35. Schifano F., (2004) A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 173, 242-248. (Pubitemid 38703797)
36. Taffe M. A., Lay C. C., Von Huben S. N., Davis S. A., Crean R. D., and, Katner S. N., (2006) Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend. 82, 276-281.
37. Touriño C., Zimmer A., and, Valverde O., (2010) THC prevents MDMA neurotoxicity in mice. PLoS ONE 5, e9143.
38. Young R., and, Glennon R. A., (2008) MDMA (N-methyl-3,4- methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol. Biochem. Behav. 88, 318-331. (Pubitemid 350116259)
39. Zhang L., Shirayama Y., Shimizu E., Iyo M., and, Hashimoto K., (2006) Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur. J. Pharmacol. 544, 1-9. (Pubitemid 44148565)